Prevalence of contraindications and prescription of pharmacologic therapies for gout

American Journal of Medicine

Volumn 124, Issue 2, 2011, Pages 155-163

  Keenan, Robert T ^a,c   O'Brien, William R ^a,c   Lee, Kristen H ^a,c   Crittenden, Daria B ^a,c   Fisher, Mark C ^a,c   Goldfarb, David S ^b,c   Krasnokutsky, Svetlana ^a,c   Oh, Cheongeun ^c   Pillinger, Michael H ^a,c  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Comorbidity; Drug contraindication; Gout; Quality of care; Treatment

Indexed keywords

ALLOPURINOL; COLCHICINE; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG CONTRAINDICATION; FEMALE; GASTROESOPHAGEAL REFLUX; GOUT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALLOPURINOL; COLCHICINE; COMORBIDITY; DIABETES MELLITUS; DRUG PRESCRIPTIONS; FEMALE; GASTROESOPHAGEAL REFLUX; GLUCOCORTICOIDS; GOUT; GOUT SUPPRESSANTS; HEPATITIS, CHRONIC; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; PROBENECID; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; URICOSURIC AGENTS;

EID: 79551674574     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2010.09.012     Document Type: Article

References (39)

1. S.Y. Kim, M.A. De Vera, and H.K. Choi Gout and mortality Clin Exp Rheumatol 26 5 Suppl 51 2008 S115 S119
2. A.J. Luk, and P.A. Simkin Epidemiology of hyperuricemia and gout Am J Manag Care 11 15 Suppl 2005 S435 S442 quiz S65-S68
3. E. Arromdee, C.J. Michet, C.S. Crowson, W.M. O'Fallon, and S.E. Gabriel Epidemiology of gout: is the incidence rising? J Rheumatol 29 2002 2403 2406
4. H.M. Kramer, and G. Curhan The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994 Am J Kidney Dis 40 2002 37 42
5. R.C. Lawrence, D.T. Felson, and C.G. Helmick Estimates of the prevalence of arthritis and other rheumatic conditions in the United States Part II Arthritis Rheum 58 2008 26 35
6. K.L. Wallace, A.A. Riedel, N. Joseph-Ridge, and R. Wortmann Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population J Rheumatol 31 2004 1582 1587
7. H.K. Choi, and E.S. Ford Prevalence of the metabolic syndrome in individuals with hyperuricemia Am J Med 120 2007 442 447
8. H.K. Choi, E.S. Ford, C. Li, and G. Curhan Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey Arthritis Rheum 57 2007 109 115
9. H. Nan, Q. Qiao, and Y. Dong The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China J Rheumatol 33 2006 1346 1350
10. J.A. Singh, J.S. Hodges, J.P. Toscano, and S.M. Asch Quality of care for gout in the US needs improvement Arthritis Rheum 57 2007 822 829
11. S.C. Zell, and J.M. Carmichael Evaluation of allopurinol use in patients with gout Am J Hosp Pharm 46 1989 1813 1816
12. T.R. Mikuls, J.R. Curtis, J.J. Allison, R.W. Hicks, and K.G. Saag Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system J Rheumatol 33 2006 562 566
13. T. Neogi, D.J. Hunter, C.E. Chaisson, D. Allensworth-Davies, and Y. Zhang Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study J Rheumatol 33 2006 104 109
14. A. Burke, E. Smyth, and G.A. Fitzgerald Analgesic-Antipyretic Agents: Pharmacotherapy of Gout Chapter 26. L.L. Brunton, Goodman & Gillman's Pharmacology 11th ed. 2006 McGraw-Hill Medical Pub. Division New York e-book accessed January 10, 2009
15. J.R. Klinenberg, S.E. Goldfinger, and J.E. Seegmiller The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout Ann Intern Med 62 1965 639 647
16. K.T. Hoskison, and R.L. Wortmann Management of gout in older adults: barriers to optimal control Drugs Aging 24 2007 21 36
17. H.F. Cheng, and R.C. Harris Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors Curr Pharm Des 11 2005 1795 1804
18. W.B. White Cardiovascular risk, hypertension, and NSAIDs Curr Rheumatol Rep 9 2007 36 43
19. B.P. Schimmer, and K.L. Parker Adrenocorticotropic Hormone: Adrenocortical Steroids and Their Synthetic Analogs: Inhibitors of the Synthesis and Actions of Adrenocortical Hormones Chapter 59. L.L. Brunton, Goodman & Gillman's Pharmacology 11th ed. 2006 McGraw-Hill Medical Pub. Division New York e-book accessed January 10, 2009
20. H.K. Choi, M.A. De Vera, and E. Krishnan Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile Rheumatology (Oxford) 47 2008 1567 1570
21. A.E. Hak, and H.K. Choi Lifestyle and gout Curr Opin Rheumatol 20 2008 179 186
22. H.K. Choi, D.B. Mount, and A.M. Reginato Pathogenesis of gout Ann Intern Med 143 2005 499 516
23. M.A. Becker, and S. Chohan We can make gout management more successful now Curr Opin Rheumatol 20 2008 167 172
24. Z. Agha, R.P. Lofgren, J.V. VanRuiswyk, and P.M. Layde Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use Arch Intern Med 160 2000 3252 3257
25. S.L. Wallace, H. Robinson, A.T. Masi, J.L. Decker, D.J. McCarty, and T.F. Yu Preliminary criteria for the classification of the acute arthritis of primary gout Arthritis Rheum 20 1977 895 900
26. A.S. Levey, J. Coresh, and E. Balk National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 2003 137 147
27. G.R. Bailie, C.A. Johnson, N.A. Mason, and W.L. St Peter Chronic Kidney Disease 2006: A Guide to Select NKF-KDOQI Guidelines and Recommendations 2006 National Kidney Foundation New York, NY http://www.kidney.org/professionals/kls/ pdf/pharmacist-CPG.pdf Accessed April 10, 2009
28. N. Schlesinger, D.F. Moore, J.D. Sun, and H.R. Schumacher Jr A survey of current evaluation and treatment of gout J Rheumatol 33 2006 2050 2052
29. FDA Prescription Drug Labeling http://www.fda.gov/downloads/Training/ ForHealthProfessionals/UCM090796.pdf Accessed Dec 6, 2010
30. R. Roubenoff, M.J. Klag, L.A. Mead, K.Y. Liang, A.J. Seidler, and M.C. Hochberg Incidence and risk factors for gout in white men JAMA 266 1991 3004 3007
31. C.A. Sarawate, K.K. Brewer, and W. Yang Gout medication treatment patterns and adherence to standards of care from a managed care perspective Mayo Clin Proc 81 2006 925 934
32. C.A. Sarawate, P.A. Patel, H.R. Schumacher, W. Yang, K.K. Brewer, and A.W. Bakst Serum urate levels and gout flares: analysis from managed care data J Clin Rheumatol 12 2006 61 65
33. A.A. Riedel, M. Nelson, K. Wallace, N. Joseph-Ridge, M. Cleary, and A.G. Fam Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting J Clin Rheumatol 10 2004 308 314
34. H. Singh, and K.D. Torralba Therapeutic challenges in the management of gout in the elderly Geriatrics 63 2008 13 18 20
35. P.G. Conaghan, and R.O. Day Risks and benefits of drugs used in the management and prevention of gout Drug Saf 11 1994 252 258
36. D. Petersel, and N. Schlesinger Treatment of acute gout in hospitalized patients J Rheumatol 34 2007 1566 1568
37. L.R. Harrold, K.G. Saag, and R.A. Yood Validity of gout diagnoses in administrative data Arthritis Rheum 57 2007 103 108
38. R.A. Terkeltaub Gout: epidemiology, pathology and pathogenesis J.H. Klippel, L.J. Crofford, J.H. Stone, C.D. Weyand, Primer on the Rheumatic Diseases 12th ed. 2001 Arthritis Foundation Atlanta, GA 307 312
39. L. Quam, L.B. Ellis, P. Venus, J. Clouse, C.G. Taylor, and S. Leatherman Using claims data for epidemiologic research The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population Med Care 31 1993 498 507